Adicet Bio to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Adicet Bio, Inc. (Nasdaq: ACET) has announced participation in three virtual investor conferences: Guggenheim Healthcare Talks (Feb 11-12), SVB Leerink Global Healthcare Conference (Feb 22-26), and H.C. Wainwright Global Life Sciences Conference (Mar 9-10). CEO Chen Schor will present on Feb 24 at 5:00 PM ET during the SVB Leerink Conference. A live audio webcast of the presentation will be available on the company's website, with an archived replay accessible for 30 days. Adicet specializes in developing allogeneic gamma delta T cell therapies for cancer and other diseases.

MENLO PARK, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that the company management will participate in three upcoming virtual investor conferences.

Details of the events are as follows:

Guggenheim Healthcare Talks 2021 Oncology Day, February 11-12, 2021
Adicet’s management team will participate in virtual investor meetings at the conference on Friday, February 12, 2021.

SVB Leerink Global Healthcare Conference, February 22-26, 2021
Chen Schor, President and Chief Executive Officer, will deliver a presentation on Wednesday, February 24, 2021 at 5:00 PM ET.

H.C. Wainwright Global Life Sciences Conference - March 9-10, 2021
Registered attendees can access the recorded presentation on-demand starting March 9, 2021 at 6:00 AM ET for the duration of the conference.

A live audio webcast of the SVB Leerink presentation can be accessed on the Investors section of Adicet Bio’s website at https://investor.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.
Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.

Adicet Bio., Inc.
Investor and Media Contacts

Anne Bowdidge
abowdidge@adicetbio.com 

Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@sternir.com 

FAQ

What are the upcoming conferences Adicet Bio (ACET) will participate in?

Adicet Bio will participate in Guggenheim Healthcare Talks (Feb 11-12), SVB Leerink Global Healthcare Conference (Feb 22-26), and H.C. Wainwright Global Life Sciences Conference (Mar 9-10).

When will Adicet Bio's CEO present at the SVB Leerink Global Healthcare Conference?

CEO Chen Schor will present on February 24, 2021, at 5:00 PM ET during the SVB Leerink Global Healthcare Conference.

How can I access the live presentation of Adicet Bio at the SVB Leerink Conference?

The live audio webcast of the presentation can be accessed on the Investors section of Adicet Bio's website during the event.

Is there a recorded version of Adicet Bio's presentation available?

Yes, an archived replay of the SVB Leerink presentation will be available for 30 days following the event.

What therapies is Adicet Bio, Inc. focused on developing?

Adicet Bio is focused on discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases.